Comments on the manuscript “Hepatorenal syndrome: an update”

Genzini T, Torricelli FC. Hepatorenal syndrome: an update. Sao Paulo Med J. 2007;125(1):50-6.

Rabelink TJ, Kaasjager KA, Boer P, Stroes EG, Braam B, Koomans HA. Effects of endo- thelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int. 1994;46(2):376-81.

Honing ML, Hijmering ML, Ballard DE, et al. Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans. J Am Soc Nephrol. 2000;11(8):1498-504.

Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation. 2004;109(9):1186-93.

Wong F, Moore K, Dingemanse J, Jalan R. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology. 2008;47(1):160-8.